Risk Evaluation and Mitigation Strategies (REMS) Rachel Bohard, PharmD Candidate
|
|
- Gabriella Patterson
- 6 years ago
- Views:
Transcription
1 Risk Evaluation and Mitigation Strategies (REMS) Rachel Bohard, PharmD Candidate
2 Objectives Define REMS. Understand the evolution of REMS. Describe components of REMS. List the factors considered by the FDA when assessing the need for REMS. Describe an example of a REMS program. Identify problems with assessing the cost and outcomes of REMS. Identify opportunities for pharmacist leadership in REMS programs.
3 History of Risk Management Most basic tools: product labeling and drug approval 1,2 1976: 1 st mandatory PPI required for oral contraceptives 1,2 1999: Medication Guides introduced : Risk Minimization Action Plans (RiskMAPs) Used to meet product-specific risk-related goals/objectives to minimize risk while sustaining benefits 1,2 For products that pose a clinically important or unusual level of risk 5 Different goals for different products Issues concerning implementation due to lack of enforcement authority
4 Risk Evaluation and Mitigation Strategies (REMS) Food and Drug Administration Amendments Act (FDAA) Title IX of 2007 authorized FDA to require and enforce (REMS) when necessary 7 Based off of RiskMAPs, but is well defined, assessed over time, and legally enforceable 1 Applies to prescription drugs and biologic products when necessary 1 Primary Goal: keeping patients safe 5 Ensures benefits outweigh risks 5 Aids in management of known risk or potential serious ADEs associated with a particular medication 5
5 Components of REMS 5 Patient Package Insert Elements to Assure Safe Use (ETASU) Communication Plan Medication Guide Figure 1 Figure 1: David KD. Food and Drug Administration. REMS Evaluations: What Have We Learned? Available at
6 Components of REMS (cont d) 5 Implementation System Monitoring, evaluating, and working to improve implementation of ETASU by pharmacists, providers, and other persons affiliated with the healthcare system Timetable for REMS Assessments (required) 18 months 3 years 7 years
7 Factors assessed by FDA when considering need for REMS 5 Population size of users Seriousness of disease Benefit expected from drug Expected treatment duration Severity of known/potential adverse events (ADEs) Whether or not the drug is a new molecular entity
8 Outcomes: Accutane (isotrentinoin) 11 Challenging to Measure Evolution of ipledge program 1 st generation risk management approach PPI and patient brochure 2 nd generation risk management approach: Pregnancy Prevention Program (PPP) Labeling changes, educational materials for counseling, 3 mandatory risk management procedures prior to prescribing Still exposed pregnancies per 1,000 patients
9 3rd generation risk management approach: System to Manage Accutane Related Teratogenicity (SMART) Improved patient education, required negative pregnancy test, qualification stickers Pregnancy rate did not decline 4th generation risk management approach: ipledge Prescribers, pharmacies, wholesaler distributers, and patients must register in database 0.012% fetal exposures versus previous 0.28% with PPP and SMART
10 Advantages of REMS Promote safe and appropriate use of drugs Provide opportunities for systematic data collection, reporting, and feedback on medication safety Allow drugs to be approved that would not otherwise have been approved because of risks Allow drugs that might have been withdrawn from the market because of risks to remain on the market Provide opportunities for expanded clinical and leadership roles and collaboration among pharmacists, physicians, and other healthcare practitioners Taken from Clinical Considerations of Risk Evaluation and Mitgivation Strategies in Health Care Systems. Risk Evaluation and Mitigation Strategies Discussion Guide.Available at
11 Disadvantages of REMS Lack of standardization Potential for Confusion among healthcare practitioners Time-consuming, labor-intensive nature Lack of reimbursement for extra work involved Insufficient healthcare practitioner input in FDA in premarketing development of REMS Potential for disruption in continuity of patient care
12 Challenges with REMS Implementation of REMS requirements Study by Childs et al. implemented qualityimprovement initiatives to increase compliance with REMS requirements 14 staff education, incorporation of REMS requirements into existing policy, development of an electronic resource, and creation of a separate storage section for drugs subject to REMS No standardization
13 Costs of REMS Challenging to quantify costs 15 Hard vs. soft costs Costs to manufacturer 15 $5,000-$500, days of development time Drug approval rates, timeline, setup and monthly maintenance 15,16 Sales impact Costs to distributers 15 $5,000- $1,000,000
14 Cost to providers 16 Offices/hospitals Policies, procedures, personnel, time, information technology Registration/certification Record keeping Reporting to manufacturer Cost to patients Accessability Time Inconvenience
15 Opportunities for pharmacist leadership 17 Actively participate in development & implementation of strategies Managing clinical & distributive therapeutic areas requiring REMS Pharmacists are uniquely qualitified Comprehension of clinical care, systems of drug distribution, attention to detail P&T Committees Continuing-education seminars
16 Publications Inservice education Professional meeting presentations Provider, resident, and student education Insight on program design and advocacy to improve program design Technician opportunities as well Record keeping
17 References 1. Choe LY. Food and Drug Administration. Risk Evaluation and Mitigation Strategies (REMS). Available at ultyprograms/pharmacystudentexperientialprogramcder/ucm pdf. Accessed May 10, Leiderman DB. Risk management of drug products and the U.S. Food and Drug Administration Evolution and context. Drug Alcohol Depend. 2009:105;S9-S Food and Drug Administration. Code of Federal Regulations: Title 21 Part 208: Medication Guides for Prescription Drug Products. 4. Trontell A. FDA Experience and Evolving Guidance on Risk Management Practices. Food and Drug Administration. Available at: Accessed May 16, Dal Pan GJ. A Short Tutorial on REMS: The FDA Perspective. Medscape. Available at Accessed May 10, Food and Drug Administration, 2005a. Guidance for Industry on the Development and Use of Risk Minimization Action Plans. Available at Accessed May 16, 2012.
18 7. Food and Drug Administration. Food and Drug Administration Amendments Act of Available at Accessed May 10, Eli Lilly and Company. Risk Evaluation and Mitigation Strategy (REMS): Zyprexa Relprevv Patient Care Program. Available at viders/ucm htm?utm_campaign=google2&utm_source=fdasearch&utm_medium=w ebsite&utm_term=rems&utm_content=1. Accessed May 16, Food and Drug Administration. ipledge March 2006 Update. Available at viders/ucm htm?utm_campaign=google2&utm_source=fdasearch&utm_medium=w ebsite&utm_term=accutane ipledge update 2006&utm_content=1. Accessed May 16, AstraZeneca Pharmaceuticals. Risk Evaluation and Mitigation Strategy (REMS): Caprelsa (vandetanib). Available at viders/ucm htm?utm_campaign=google2&utm_source=fdasearch&utm_medium=w ebsite&utm_term=rems&utm_content=1. Accessed May 16, Abroms L, Maibach E, Lyon-Daniel K, et al. What is the Best Approach to Reducing Birth Control Defects? PLoS Med. 2006:3(11):e483.
19 12. Traynor K. American Society of Health-System Pharmacists. RENS Review Explores Programs Burdens. Available at ss&id=3651. Accessed May 16, Chung R. Tufts Center for the Study of Drug Development. U.S. Healthcare Stakeholders Uncertain about Benefits of Risk Evaluation Program. Available at Accessed May 22, Childs L, Alexander E, Duong M. Risk evaluation and mitigation strategies: Assessment of a medical center s policies and procedures. Am J Health-Syst Pharm. 2012:69; Miller G. Fierce Pharma Manufacturing. REMS costs calculated in study. Available at Accessed May 16, Decisive Bio-Insight. Risk Evaluation and Mitigation Strategies (REMS) Trends and Implications for Bio-Pharma. Available at Accessed May 11, Clinical Considerations of Risk Evaluation and Mitgivation Strategies in Health Care Systems. Risk Evaluation and Mitigation Strategies Discussion Guide. Available at Accessed May 22, Stubbing J, Joshi RA, Hoffman JM. Risk evaluation and mitigation strategies: Challenges and opportunities for health-system pharmacists. Am J Health-Syst Pharm. 2010:67;
Objectives. Hospital Pharmacy Strategies for REMS. Evolution of FDA Drug Safety Programs. REMS: Definition. Evolution of FDA Drug Safety Programs
Objectives Hospital Pharmacy Strategies for REMS SCSHP Fall Meeting October 28, 2010 John Pearson, PharmD, BCNSP, BCPS Manager, Pharmacy Clinical Services Greenville Hospital System University Medical
More informationTo understand the formulary process from the hospital perspective
Formulary Process Christine L. Ahrens, Pharm.D. Cleveland Clinic Cleveland Clinic 2011 Goal and Objectives To understand the formulary process from the hospital perspective p To list the various panels
More informationAdditional Risk Minimisation and Burden: A CIOMS IX Perspective. Stephen Heaton, MD BayerHealthCare Member of CIOMS IX Working Group
Additional Risk Minimisation and Burden: A CIOMS IX Perspective Stephen Heaton, MD BayerHealthCare Member of CIOMS IX Working Group Disclaimer The views and opinions expressed in the following PowerPoint
More informationNEW JERSEY. Downloaded January 2011
NEW JERSEY Downloaded January 2011 SUBCHAPTER 29. MANDATORY PHARMACY 8:39 29.1 Mandatory pharmacy organization (a) A facility shall have a consultant pharmacist and either a provider pharmacist or, if
More informationNATPARA REMS PROGRAM. Frequently Asked Questions (FAQ)
1 2 3 4 5 What is a Risk Evaluation and Mitigation Strategy (REMS)? A Risk Evaluation and Mitigation Strategy (REMS) is a strategy to manage known or potential serious risks associated with a drug or biologic
More informationIsotretinoin : Review of the Pregnancy Prevention Programme
Safeguarding public health Isotretinoin : Review of the Pregnancy Prevention Programme HCP WG meeting October 2011: Dr Sarah Mee Isotretinoin: UK RMS Introduction In 2003, European referral led to introduction
More informationSeptember 16 th, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
September 16 th, 2013 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2013-N-0502: Standardizing and Evaluating Risk
More informationSpecialty Pharmacy How is Traditional Pharmacy Practice Positioned
Specialty Pharmacy How is Traditional Pharmacy Practice Positioned Nick Calla Vice President, Industry Relations Cardinal Health Specialty Solutions August 19, 2016 Today s Learning Objectives Understand
More informationPharmacy Leadership and Administration Learning Experience Rev 12/16/16
Pharmacy Leadership and Administration Learning Activities (Longitudinal): Preceptors: Jordan Dow, PharmD MS FACHE (Regional Pharmacy Director); Michele Richmond, RPh (Outpatient Pharmacy Director); Maggie
More informationOrientation to Risk Evaluation and Mitigation Strategies (REMS)
Orientation to Risk Evaluation and Mitigation Strategies (REMS) Gary Slatko, MD Director, Off of Medication Error Prevention and Risk Management, OSE, CDER, FDA September 25, 2013 1 Background The REMS
More informationOmnibus Budget Reconciliation Act of 1990 and 1993
Omnibus Budget Reconciliation Act of 1990 and 1993 Pantea Ghasemi, USC Pharm.D. Candidate of 2015 Sarkis Kavarian, UOP Pharm.D. Candidate of 2015 Preceptor Dr. Craig Stern Pro Pharma Pharmaceutical Consultants,
More informationImproving the Patient Experience Through Pharmacy
Rick Burnett Chief Operating Officer Kenneth Maxik Director, Patient Safety & Pharmacy Compliance Improving the Patient Experience Through Pharmacy August 19, 2015 Speakers Rick Burnett, PharmD, FACHE
More informationStatement of Ronna B. Hauser, Pharm.D. Vice President, Policy and Regulatory Affairs National Community Pharmacists Association
Statement of Ronna B. Hauser, Pharm.D. Vice President, Policy and Regulatory Affairs National Community Pharmacists Association Food and Drug Administration [Docket Nos. FDA 2010 N 0284 and FDA 2009 D
More informationDiploma In Drug & Pharmacy CURRICULUM/SYLLABUS. Course Code: 8274
Diploma In Drug & Pharmacy CURRICULUM/SYLLABUS Course Code: 8274 This program is aimed at training candidates for the job of a Working in Medical Stores or in Pharmacy Company where he/she can able to
More information5ESSB 5857 Regulation Pharmacy Benefit Managers Signed into law April 1, 2016
WSPA/LRAC Bill Tracking Update April 18, 2016 FINAL REPORT 5ESSB 5857 Regulation Pharmacy Benefit Managers Signed into law April 1, 2016 Transfers regulatory oversight of Pharmacy Benefit Manager (PBMs)
More informationPerformance Measurement of a Pharmacist-Directed Anticoagulation Management Service
Hospital Pharmacy Volume 36, Number 11, pp 1164 1169 2001 Facts and Comparisons PEER-REVIEWED ARTICLE Performance Measurement of a Pharmacist-Directed Anticoagulation Management Service Jon C. Schommer,
More informationSFHPHARM11 - SQA Unit Code FA2X 04 Prepare extemporaneous medicines for individual use
Prepare extemporaneous medicines for individual use Overview This standard covers your role in preparing extemporaneous medicines for individual use. This involves accurately calculating the quantities
More informationDrug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug
This document is scheduled to be published in the Federal Register on 03/14/2016 and available online at http://federalregister.gov/a/2016-05573, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationMedication Errors in Chemotherapy PORSCHA L. JOHNSON, PHARM.D. CLINICAL PHARMACIST II MEDSTAR WASHINGTON HOSPITAL CENTER SATURDAY, SEPTEMBER 17, 2016
Medication Errors in Chemotherapy PORSCHA L. JOHNSON, PHARM.D. CLINICAL PHARMACIST II MEDSTAR WASHINGTON HOSPITAL CENTER SATURDAY, SEPTEMBER 17, 2016 DISCLOSURE STATEMENT I have nothing to disclose regarding
More informationPosition Statement on Prescription Drug Shortages in Canada
CMA POLICY Position Statement on Prescription Drug Shortages in Canada The escalation in shortages of prescription drugs in the past few years and the ongoing disruptions to supply experienced in Canada
More informationRisk Evaluation and Mitigation Strategies: Improving Benefit-Risk Counseling Between Providers and Patients 4/14/2016
Risk Evaluation and Mitigation Strategies: Improving Benefit-Risk Counseling Between Providers and Patients 4/14/2016 1 Gary Slatko Sara Eggers U.S. Food and Drug Administration 2 Goals for Today s Meeting
More informationDC Board of Pharmacy and Pharmaceutical Control Update
DC Board of Pharmacy and Pharmaceutical Control Update Patricia M. D Antonio, RPh, MS, MBA,CGP Executive Director, Board of Pharmacy Program Manager, Pharmaceutical Control May 30, 2015 Organization Health
More informationPharmaceutical Services Requirements: formerly 10D and 10C.7
Pharmaceutical Services Requirements: formerly 10D.28-29 and 10C.7 Frank S. Emanuel, Pharm.D., FASHP Associate Professor/Division Director Florida A and M University College of Pharmacy Jacksonville Disclosure
More informationEuropean Association of Hospital Pharmacists (EAHP)
European Association of Hospital Pharmacists (EAHP) Consultation Response Delegated Act on the detailed rules for a unique identifier for medicinal products for human use, and its verification. April 2012
More informationEVALUATION OF THE FINANCIAL IMPACT OF MEDICATION BACKORDERS IN A TERTIARY CARE HOSPITAL. Kalyn Marie Acker
EVALUATION OF THE FINANCIAL IMPACT OF MEDICATION BACKORDERS IN A TERTIARY CARE HOSPITAL by Kalyn Marie Acker PharmD, University of Texas at Austin, 2015 BS in Biochemistry, Texas Tech University, 2011
More informationPharmacy Operations. General Prescription Duties. Pharmacy Technician Training Systems Passassured, LLC
Pharmacy Operations General Prescription Duties Pharmacy Technician Training Systems Passassured, LLC Pharmacy Operations, General Prescription Duties PassAssured's Pharmacy Technician Training Program
More information340B DRUG PRICING PROGRAM
340B DRUG PRICING PROGRAM Lindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy Pro Pharma Pharmaceutical Consultants, Inc. Under the preceptorship of Dr. Craig Stern
More informationDrug Shortage Preparedness
PURDUE UNIVERSITY COLLEGE OF PHARMACY S CENTER FOR MEDICATION SAFETY ADVANCEMENT Drug Shortage Preparedness Survey and Tips for Improvement Developed by: Jonathan Weir, PharmD Candidate in collaboration
More information79th OREGON LEGISLATIVE ASSEMBLY Regular Session. Enrolled
79th OREGON LEGISLATIVE ASSEMBLY--2017 Regular Session Enrolled House Bill 2527 Sponsored by Representative BUEHLER, Senator STEINER HAYWARD; Representatives HACK, KENY-GUYER, SOLLMAN, Senator MONNES ANDERSON
More informationTopic: CAP s Legislative Proposal for Laboratory-Developed Tests (LDT) Date: September 14, 2015
Topic: CAP s Legislative Proposal for Laboratory-Developed Tests (LDT) Date: September 14, 2015 1. What are the CAP s views on the regulatory oversight of laboratory-developed tests (LDTs)? 2. How are
More informationDose Administration Aid Patient Detect Service
Dose Administration Aid Patient Detect Service Protocol October 2015 Version 1.3 Table of Contents Executive Summary... 1 Program objective... 1 Patient qualification... 2 Clinical Service... 2 Reporting/Claiming...
More informationWHITE PAPER: US FDA REMS
WHITE PAPER: US FDA REMS Standardization; a prerequisite to improving healthcare provider application of patient-directed tools and medication risk reduction strategies for reducing patient harm Author:
More informationNew Alignments in Data-Driven Care Coordination & Access for Specialty Products: Insights from the DIMENSIONS Report
New Alignments in Data-Driven Care Coordination & Access for Specialty Products: Insights from the DIMENSIONS Report Our Objectives By the end of the session, participants will understand: Evolving demands
More informationAdministration of Oral Prescription Medication Procedure Page 1 of 6
Page 1 of 6 RATIONALE: Hamilton-Wentworth District School Board is committed to ensuring the provision of plans, programs, and/or services that will enable students with health or medical needs to attend
More informationPatient Safety Opportunity (CEI)
Patient Safety Opportunity (CEI) Adverse Drug Event Surveillance Rachel Digmann, Pharm.D, BCPS Medication Safety & Program Lead Quality Innovation Network-National Coordinating Center Telligen Disclosures
More informationWhat does governance look like in homecare?
What does governance look like in homecare? Dr David Cousins PhD FRPharmS Head of Pa)ent Safety, Healthcare at Home Ltd This Satellite is sponsored by Healthcare at Home Ltd Definitions Clinical governance
More information3 HEALTH, SAFETY AND ENVIRONMENTAL PROTECTION
1 PURPOSE The purpose of this procedure is to describe the method by which Adverse Events (AE)/relevant Safety Information and Product Quality Complaints (PQC) will be received, triaged, and documented
More informationPolicies Approved by the 2017 ASHP House of Delegates
House of Delegates Policies Approved by the 2017 ASHP House of Delegates 1701 Ensuring Patient Safety and Data Integrity During Cyber-attacks Source: Council on Pharmacy Management To advocate that healthcare
More information78th OREGON LEGISLATIVE ASSEMBLY Regular Session. House Bill 2028 SUMMARY
Sponsored by COMMITTEE ON HEALTH CARE th OREGON LEGISLATIVE ASSEMBLY-- Regular Session House Bill SUMMARY The following summary is not prepared by the sponsors of the measure and is not a part of the body
More informationPOLICY AND PROCEDURE DEPARTMENT: Pharmacy Operations
PAGE: 1 of 6 SCOPE: Centene Corporate Pharmacy Department, Centene Corporate Pharmacy and Therapeutics Committee, Health Plan Pharmacy Departments, Health Plan Pharmacy and Therapeutics Committees, and
More informationTechnologies in Pharmacology
Technologies in Pharmacology OBJECTIVES/RATIONALE Modern health care is increasingly dependent upon technology. Health care workers must be able to select appropriate equipment and instruments and use
More informationPetitioner's Guide for Recognition of a Pharmacy Practice Specialty
Board of Pharmacy Specialties Petitioner's Guide for Recognition of a Pharmacy Practice Specialty I. Introduction II. III. IV. Criteria for Specialty Recognition BPS Procedures for Considering Petitions
More informationRULES OF TENNESSEE DEPARTMENT OF LABOR AND WORKFORCE DEVELOPMENT WORKERS COMPENSATION DIVISION
RULES OF TENNESSEE DEPARTMENT OF LABOR AND WORKFORCE DEVELOPMENT WORKERS COMPENSATION DIVISION CHAPTER 0800-02-25 WORKERS COMPENSATION MEDICAL TREATMENT TABLE OF CONTENTS 0800-02-25-.01 Purpose and Scope
More informationELECTIVE COMPETENCY AREAS, GOALS, AND OBJECTIVES FOR POSTGRADUATE YEAR ONE (PGY1) PHARMACY RESIDENCIES
ELECTIVE COMPETENCY AREAS, GOALS, AND OBJECTIVES FOR POSTGRADUATE YEAR ONE (PGY1) PHARMACY RESIDENCIES Introduction The competency areas, goals, and objectives are for use with the ASHP Accreditation Standard
More informationLEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS
LEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS Joey Gouws MCC and Cluster: Food Control, Pharmaceutical Trade and Product Regulation NATIONAL DEPARTMENT OF HEALTH
More informationPostmarketing Drug Safety and Inspection Readiness
Postmarketing Drug Safety and Inspection Readiness June 19, 2018 Center for Drug Evaluation and Research (CDER) Small Business and Industry Assistance (SBIA) Webinar United States Food and Drug Administration
More informationImplementation of Student Pharmacist-Led Anticoagulation Counseling
Implementation of Student Pharmacist-Led Anticoagulation Counseling Jamie Sebaaly, PharmD Candidate Class of 2013 UNC Eshelman School of Pharmacy Co-Investigator: Jenna M. Huggins, PharmD, BCPS Clinical
More informationThis document provides information on conducting the Perindopril New To Therapy Program using GuildCare software.
Perindopril New To Therapy Program PROTOCOL This document provides information on conducting the Perindopril New To Therapy Program using GuildCare software. April 2015 Table of Contents Executive Summary...
More informationUNMC COLLEGE OF PHARMACY ADVANCED PHARMACY PRACTICE EXPERIENCE (APPE) SYLLABUS (Revised February 2013, Approved April 2013)
UNMC COLLEGE OF PHARMACY ADVANCED PHARMACY PRACTICE EXPERIENCE (APPE) SYLLABUS (Revised February 2013, Approved April 2013) COURSE TITLE: Drug Utilization Review at Nebraska Pharmacists Association (NPA)
More informationCEOCFO Magazine. Andy Reeves, RPh Chief Executive Officer OptiMed Specialty Pharmacy
CEOCFO Magazine ceocfointerviews.com All rights reserved! Issue: October 30, 2017 Q&A with Andy Reeves, RPh, CEO of OptiMed Specialty Pharmacy, a National Specialty and Infusion Pharmacy dedicated to Managing
More informationChapter 1: Overview of Texas Pharmacy Law 1 Contact Hour (Mandatory)
Chapter 1: Overview of Texas Pharmacy Law 1 Contact Hour (Mandatory) By: Katie Blair, PharmD, RPh Author Disclosure: Katie Blair and Elite Professional Education, LLC do not have any actual or potential
More informationGood Practice Principles:
NHMC National Homecare Medicines Committee Good Practice Principles: Provision of Manufacturer Funded Homecare Medicines Services National Homecare Medicines Committee February 2018 Version 1 Definitions
More informationRISK EVALUATION AND MITIGATION STRATEGY (REMS)
Initial REMS approval: XX/XXXX NDA 21338 IONSYS (fentanyl iontophoretic transdermal system) I. GOAL Fentanyl/Opioid The Medicines Company 8 Sylvan Way, Parsippany NJ 07054 Phone: 973-290-6050 RISK EVALUATION
More informationSpecialty Pharmacy: What You Need To Know. William Pong, Pharm.D., MBA
Specialty Pharmacy: What You Need To Know William Pong, Pharm.D., MBA DISCLOSURE I have no actual or potential conflict of interest in relation to this program/ presentation OBJECTIVEs Navigating the landscape
More information2017 ASHP Proposed Policies: To Approve or Not to Approve, That is the Question. Disclosures. Learning Objectives 3/16/2017
2017 ASHP Proposed Policies: To Approve or Not to Approve, That is the Question Nicole Allcock, PharmD, BCPS, FASHP Noelle RM Chapman, PharmD, BCPS, FASHP Joel Hennenfent, PharmD, MBA, BCPS, FASHP Jen
More informationHCA 302 Module 5 Lecture Notes The Pharmaceutical Industry and Health Care Workforce
HCA 302 Module 5 Lecture Notes The Pharmaceutical Industry and Health Care Workforce Why are pharmaceuticals important? The Pharmaceutical Industry has influence, in part because it represents 10% of the
More informationMarketing. Pharmaceutical Industry: Marketing Positions 445
Marketing Pharmaceutical Industry: Marketing Positions 445 Restricted Drug Distribution (1714) To oppose restricted drug distribution systems that (1) limit patient access to medications; (2) undermine
More informationBringing the Clinical Mindset to the Retail Pharmacist
Bringing the Clinical Mindset to the Retail Pharmacist Sarah Griffin, Pharm.D. Harding University College of Pharmacy White County Medical Center Objectives Describe challenging situations faced by pharmacists
More informationORGANIZATION OF AMERICAN STATES
ORGANIZATION OF AMERICAN STATES INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION GROUP OF EXPERTS ON PHARMACEUTICAL PRODUCTS Guide for health professionals concerning counterfeit drugs Bahamas - Brasil Lima,
More informationFive Rights of Medication
Five Rights of Medication Lack of knowledge has been implicated in many medication errors; therefore, education about broadly stated goals and practices to safely administer medications is essential. Medication
More informationPresentation to the Federal, Provincial and Territorial (FPT) Deputy Ministers of Health Meeting
Presentation to the Federal, Provincial and Territorial (FPT) Deputy Ministers of Health Meeting Gatineau, Quebec June 10, 2011 (Amended for Project Web Page) Canadian Pharmaceutical Bar Coding Project
More informationSuccessfully maintaining a formulary that represents
in a Large, Multihospital System Laura BeQuette, PharmD; Joseph K. Jordan, PharmD, BCPS; Amy Heck Sheehan, PharmD; and James A. Jorgenson, MS, RPh At a Glance Practical Implications p 320 Author Information
More informationProfiles in CSP Insourcing: Tufts Medical Center
Profiles in CSP Insourcing: Tufts Medical Center Melissa A. Ortega, Pharm.D., M.S. Director, Pediatrics and Inpatient Pharmacy Operations Tufts Medical Center Hospital Profile Tufts Medical Center (TMC)
More informationObjectives. Reality Tech Check: Standardizing Certification of Pharmacy Technicians. Pre Test Question. Pre Test Question.
Reality Tech Check: Standardizing Certification of s Desi Kotis, Pharm.D., FASHP Brittany Huff, Pharm.D. The Speakers Have Nothing to Disclose Objectives Explain the value that s and pharmacy technicians
More information17th Annual ASHP Conference for Leaders in Health-System Pharmacy
17th Annual ASHP Conference for Leaders in Health-System Pharmacy Lee Vermeulen, M.S., B.S.Pharm., FCCP Health Care Transitions: What Trends Are Next for the Front-line Leader? Activity Overview Pharmacy
More informationImplementing USP 800 ASHLEY DUTY, PHARMD, MS JOANNA ROBINSON, PHARMD, MS
Implementing USP 800 ASHLEY DUTY, PHARMD, MS JOANNA ROBINSON, PHARMD, MS Disclosure Ashley Duty has no conflicts of interest to disclose Joanna Robinson has no conflicts of interest to disclose Objectives
More informationImplementing USP 800 ASHLEY DUTY, PHARMD, MS JOANNA ROBINSON, PHARMD, MS
Implementing USP 800 ASHLEY DUTY, PHARMD, MS JOANNA ROBINSON, PHARMD, MS Disclosure Ashley Duty has no conflicts of interest to disclose Joanna Robinson has no conflicts of interest to disclose Objectives
More informationIntroduction to Post-marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER
Introduction to Post-marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER Sara Camilli, PharmD, BCPS, Safety Evaluator Team Leader Selena Ready, PharmD, CGP, Safety Evaluator Division of Pharmacovigilance
More informationChapter 3 Products, Networks, and Payment Unit 4: Pharmacy and Formulary
Chapter 3 Products, Networks, and Payment Unit 4: Pharmacy and Formulary In This Unit Topic See Page Unit 4: Pharmacy and Formulary Pharmaceutical Overview 2 Pharmaceutical 3 Drug 4 NOTE: This section
More informationEffective Date: 11/09 Policy Chronicle:
Title: Investigational Drug Service Functions Policy Type: Clinical Operations Replaces (supersedes): Title: N/A Policy Chronicle: Date Original Version of Policy was Effective: 09/06 Reviewer Signature:
More informationDetermining and Reporting Adverse Events vs. Product Complaints
Determining and Reporting Adverse Events vs. Product Complaints Pharma Perspective: Jacqueline Grissinger Director, Office of Consumer Medical Safety Johnson & Johnson Medical Device Perspective: Lisa
More informationUnlicensed medicines ( specials ) Current issues related to unlicensed medicines and a suggested approach to devising a coherent sourcing strategy
Unlicensed medicines ( specials ) Current issues related to unlicensed medicines and a suggested approach to devising a coherent sourcing strategy Andrew Tittershill Content Personal introduction. Defining
More informationInstitutional Medication Dispensing Categories: Medication Waste and Cost Savings Analysis
Institutional Medication Dispensing Categories: Medication Waste and Cost Savings Analysis Paige Garber, PharmD PGY2 Critical Care Pharmacy Resident Katie McKinney, PharmD, MS, BCPS Director, Pharmacy
More informationRequest for Proposal: Primary Medication Non-Adherence
Request for Proposal: Primary Medication Non-Adherence Release date: January 4, 2011 Due date: March 15, 2011 Interested stakeholders are encouraged to participate in the NACDS Foundation conference call
More informationPharmacovigilance & Managed Care Pharmacy. Issues for Medication Safety in Korea
Pharmacovigilance and Managed Care Pharmacy Issues for Medication Safety in Korea Hyun Taek Shin, Pharm.D. Professor, College of Pharmacy Sookmyung University & President, Korean Academy of Managed Care
More informationEXPERIENTIAL EDUCATION Medication Therapy Management Services Provided by Student Pharmacists
EXPERIENTIAL EDUCATION Medication Therapy Management Services Provided by Student Pharmacists Micah Hata, PharmD, a Roger Klotz, BSPharm, a Rick Sylvies, PharmD, b Karl Hess, PharmD, a Emmanuelle Schwartzman,
More informationIMPACT OF TECHNOLOGY ON MEDICATION SAFETY
Continuous Quality Improvement IMPACT OF Steven R. Abel, PharmD, FASHP TECHNOLOGY ON Nital Patel, PharmD. MBA MEDICATION SAFETY Sheri Helms, PharmD Candidate Brian Heckman, PharmD Candidate Ismaila D Badjie
More informationInternational Pharmaceutical Federation Fédération internationale pharmaceutique. Standards for Quality of Pharmacy Services
International Pharmaceutical Federation Fédération internationale pharmaceutique PO Box 84200, 2508 AE The Hague, The Netherlands Standards for Quality of Pharmacy Services Standards are an important part
More informationCDER Small Business and Industry Assistance (SBIA)
CDER Small Business and Industry Assistance (SBIA) Brenda Stodart, PharmD, BCGP Director CDER Small Business and Industry Assistance (SBIA) Division of Drug Information (DDI) Center for Drug Evaluation
More informationHelping physicians care for patients Aider les médecins à prendre soin des patients
CMA s Response to Health Canada s Consultation Questions Regulatory Framework for the Mandatory Reporting of Adverse Drug Reactions and Medical Device Incidents by Provincial and Territorial Healthcare
More informationCanada s Multi-Stakeholder Approach to Drug Shortages
Canada s Multi-Stakeholder Approach to Drug Shortages Health Canada Presentation to the Canadian Agency For Drugs And Technologies In Health April X, 2017 Overview Context A Collaborative Multi-Stakeholder
More informationPatient Section All fields are required. Please print clearly and complete all information.
Lilly Cares Foundation Patient Assistance Program PO Box 13185 La Jolla, CA 92039 Phone: 1-800-545-6962 Fax: 1-844-431-6650 www.lillycares.com Patient Section All fields are required. Please print clearly
More informationMedication Reconciliation: Using Pharmacy Technicians to Improve Care. Becky Johnson, CPhT Megan Ohrlund, PharmD Steve Finch, RPh
Medication Reconciliation: Using Pharmacy Technicians to Improve Care Becky Johnson, CPhT Megan Ohrlund, PharmD Steve Finch, RPh Objectives Evaluate the medication reconciliation process and evidence for
More informationThis document replaces the versions originally posted on August 3, 2017 and September 11, 2017.
Frequently Asked Questions for Health Care Providers: Dispensing of Mifepristone/ misoprostol (Mifegymiso) and Claims Submission using the Health Network System Updated December 7, 2017 This document replaces
More informationMedication Reconciliation: Using Pharmacy Technicians to Improve Care. Objectives THE BASICS AND USING TECHNICIANS 3/22/2017
Medication Reconciliation: Using Pharmacy Technicians to Improve Care Becky Johnson, CPhT Megan Ohrlund, PharmD Steve Finch, RPh Objectives Evaluate the medication reconciliation process and evidence for
More informationTricks of the Trade: Formulary Management in a Health System
Tricks of the Trade: Formulary Management in a Health System Mandy C. Leonard, Pharm.D., BCPS System Director, Drug Use Policy and Formulary Management Department of Pharmacy Cleveland Clinic April 11,
More information4/9/2013. Best Practice Initiative: Inpatient Anticoagulation Stewardship. Dorcas Letting reports no relevant financial relationships
Disclosure Best Practice Initiative: Inpatient Anticoagulation Stewardship Dorcas Letting reports no relevant financial relationships Dorcas Letting-Mangira, Pharm.D Pharmacotherapist, Internal Medicine
More informationPatient-Centered Connected Care 2015 Recognition Program Overview. All materials 2016, National Committee for Quality Assurance
Patient-Centered Connected Care 2015 Recognition Program Overview All materials 2016, National Committee for Quality Assurance Learning Objectives Introduction to Patient-Centered Connected Care and Eligibility
More informationTherefore the provision of medicines is an area for which a Community regulatory framework should be properly supervised to ensure full and
European Association of Pharmaceutical Full-line Wholesalers (GIRP) response to the European Commission Consultation regarding Community action on Health Services Introduction Firstly, GIRP welcomes the
More informationH 5497 S T A T E O F R H O D E I S L A N D
LC000 01 -- H S T A T E O F R H O D E I S L A N D IN GENERAL ASSEMBLY JANUARY SESSION, A.D. 01 A N A C T RELATING TO BUSINESSES AND PROFESSIONS - PHARMACIES Introduced By: Representatives Serpa, and Fellela
More informationMedication Reconciliation in Transitions of Care
Medication Reconciliation in Transitions of Care Jeff West, RN MPH June 18th, 2015 Adverse Drug Events & Readmissions For every 1,000 hospital admissions, medication reconciliation could prevent 14 adverse
More informationAn Overview for Inpatient Pharmacies (e.g., hospitals, in-hospital hospices, and long-term care facilities that dispense for inpatient use)
The Transmucosal Immediate Release Fentanyl (TIRF) REMS Access Program An Overview for Inpatient Pharmacies (e.g., hospitals, in-hospital hospices, and long-term care facilities that dispense for inpatient
More informationAdvancing MN Pharmacy 2016 Advocacy Accomplishments & 2017 Plans
Advancing MN Pharmacy 2016 Advocacy Accomplishments & 2017 Plans Jill Strykowski and Michelle Aytay MPhA Public Affairs Co Chairs, PPAJTF Session Objectives Outline the outcomes from the 2016 Legislative
More informationDisclosures. Objectives. Leveraging and Developing Your Team for Optimal Outcomes. None
Leveraging and Developing Your Team for Optimal Outcomes Michelle W. McCarthy, PharmD, FASHP Coordinator, Pharmacy Education and Graduate Programs Charlottesville, VA November 6, 2017 Disclosures None
More informationApplication Form Instructions
Lilly Cares Foundation Patient Assistance Program PO Box 13185 La Jolla, CA 92039 1-800-545-6962 Fax: (844) 431-6650 www.lillycares.com The Lilly Cares Foundation, Inc., a separate nonprofit foundation,
More informationNHS Lanarkshire Policy for the Availability of Unlicensed Medicines
NHS Lanarkshire Policy for the Availability of Unlicensed Medicines Prepared by: NHS Lanarkshire Chief Pharmacist Endorsed by: Area Drug & Therapeutic Committee Previous Version/Date: Primary Policy Date:
More informationMedication Assisted Treatment for Opioid Use Disorders Reporting Requirements
This document is scheduled to be published in the Federal Register on 09/27/2016 and available online at https://federalregister.gov/d/2016-23277, and on FDsys.gov DEPARTMENT OF HEALTH AND HUMAN SERVICES
More informationMeasuring the Cost Effectiveness of Pharmacogenomic Testing
Measuring the Cost Effectiveness of Pharmacogenomic Testing Kenneth Levy, Ph.D., MBA Adjunct Associate Professor of Medicine Indiana University School of Medicine Disclosures: The author has no disclosures
More informationNew Jersey issues rules to chill drug manufacturer payments to prescribers
New Jersey issues rules to chill drug manufacturer payments to prescribers January 10, 2018 The New Jersey Attorney General plans to finalize new limits on payments and other benefits that New Jersey licensed
More informationAN ACT. Be it enacted by the General Assembly of the State of Ohio:
(131st General Assembly) (Substitute House Bill Number 124) AN ACT To amend section 4729.01 and to enact sections 4723.4810, 4729.282, 4730.432, and 4731.93 of the Revised Code regarding the authority
More information